High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy

Xiaofeng Fan, Qing Mao, Donghui Zhou, Yang Lu, Jianwei Xing, Yanjuan Xu, Stuart Campbell Ray, Adrian M. Di Bisceglie

Research output: Contribution to journalArticle

Abstract

Differential response patterns to optimal antiviral therapy, peginterferon alpha plus ribavirin, are well documented in patients with chronic hepatitis C virus (HCV) infection. Among many factors that may affect therapeutic efficiency, HCV quasispecies (QS) characteristics have been a major focus of previous studies, yielding conflicting results. To obtain a comprehensive understanding of the role of HCV QS in antiviral therapy, we performed the largest-ever HCV QS analysis in 153 patients infected with HCV genotype 1 strains. A total of 4,314 viral clones spanning hypervarible region 1 were produced from these patients during the first 12 weeks of therapy, followed by detailed genetic analyses. Our data show an exponential distribution pattern of intrapatient QS diversity in this study population in which most patients (63%) had small QS diversity with genetic distance (d) less than 0.2. The group of patients with genetic distance located in the decay region (d>0.53) had a significantly higher early virologic response (EVR) rate (89.5%), which contributed substantially to the overall association between EVR and increased baseline QS diversity. In addition, EVR was linked to a clustered evolutionary pattern in terms of QS dynamic changes. Conclusion: EVR is associated with elevatedHCVQS diversity and complexity, especially in patients with significantly higher HCV genetic heterogeneity.

Original languageEnglish (US)
Pages (from-to)1765-1772
Number of pages8
JournalHepatology
Volume50
Issue number6
DOIs
StatePublished - 2009

Fingerprint

Hepatitis C
Hepacivirus
Antiviral Agents
Therapeutics
Genetic Heterogeneity
Ribavirin
Chronic Hepatitis C
Virus Diseases
Clone Cells
Genotype
Population

ASJC Scopus subject areas

  • Hepatology

Cite this

High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy. / Fan, Xiaofeng; Mao, Qing; Zhou, Donghui; Lu, Yang; Xing, Jianwei; Xu, Yanjuan; Ray, Stuart Campbell; Di Bisceglie, Adrian M.

In: Hepatology, Vol. 50, No. 6, 2009, p. 1765-1772.

Research output: Contribution to journalArticle

Fan, Xiaofeng ; Mao, Qing ; Zhou, Donghui ; Lu, Yang ; Xing, Jianwei ; Xu, Yanjuan ; Ray, Stuart Campbell ; Di Bisceglie, Adrian M. / High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy. In: Hepatology. 2009 ; Vol. 50, No. 6. pp. 1765-1772.
@article{d1dd08bc068d45c49c22693bad7bbe4d,
title = "High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy",
abstract = "Differential response patterns to optimal antiviral therapy, peginterferon alpha plus ribavirin, are well documented in patients with chronic hepatitis C virus (HCV) infection. Among many factors that may affect therapeutic efficiency, HCV quasispecies (QS) characteristics have been a major focus of previous studies, yielding conflicting results. To obtain a comprehensive understanding of the role of HCV QS in antiviral therapy, we performed the largest-ever HCV QS analysis in 153 patients infected with HCV genotype 1 strains. A total of 4,314 viral clones spanning hypervarible region 1 were produced from these patients during the first 12 weeks of therapy, followed by detailed genetic analyses. Our data show an exponential distribution pattern of intrapatient QS diversity in this study population in which most patients (63{\%}) had small QS diversity with genetic distance (d) less than 0.2. The group of patients with genetic distance located in the decay region (d>0.53) had a significantly higher early virologic response (EVR) rate (89.5{\%}), which contributed substantially to the overall association between EVR and increased baseline QS diversity. In addition, EVR was linked to a clustered evolutionary pattern in terms of QS dynamic changes. Conclusion: EVR is associated with elevatedHCVQS diversity and complexity, especially in patients with significantly higher HCV genetic heterogeneity.",
author = "Xiaofeng Fan and Qing Mao and Donghui Zhou and Yang Lu and Jianwei Xing and Yanjuan Xu and Ray, {Stuart Campbell} and {Di Bisceglie}, {Adrian M.}",
year = "2009",
doi = "10.1002/hep.23290",
language = "English (US)",
volume = "50",
pages = "1765--1772",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - High diversity of hepatitis C viral quasispecies is associated with early virological response in patients undergoing antiviral therapy

AU - Fan, Xiaofeng

AU - Mao, Qing

AU - Zhou, Donghui

AU - Lu, Yang

AU - Xing, Jianwei

AU - Xu, Yanjuan

AU - Ray, Stuart Campbell

AU - Di Bisceglie, Adrian M.

PY - 2009

Y1 - 2009

N2 - Differential response patterns to optimal antiviral therapy, peginterferon alpha plus ribavirin, are well documented in patients with chronic hepatitis C virus (HCV) infection. Among many factors that may affect therapeutic efficiency, HCV quasispecies (QS) characteristics have been a major focus of previous studies, yielding conflicting results. To obtain a comprehensive understanding of the role of HCV QS in antiviral therapy, we performed the largest-ever HCV QS analysis in 153 patients infected with HCV genotype 1 strains. A total of 4,314 viral clones spanning hypervarible region 1 were produced from these patients during the first 12 weeks of therapy, followed by detailed genetic analyses. Our data show an exponential distribution pattern of intrapatient QS diversity in this study population in which most patients (63%) had small QS diversity with genetic distance (d) less than 0.2. The group of patients with genetic distance located in the decay region (d>0.53) had a significantly higher early virologic response (EVR) rate (89.5%), which contributed substantially to the overall association between EVR and increased baseline QS diversity. In addition, EVR was linked to a clustered evolutionary pattern in terms of QS dynamic changes. Conclusion: EVR is associated with elevatedHCVQS diversity and complexity, especially in patients with significantly higher HCV genetic heterogeneity.

AB - Differential response patterns to optimal antiviral therapy, peginterferon alpha plus ribavirin, are well documented in patients with chronic hepatitis C virus (HCV) infection. Among many factors that may affect therapeutic efficiency, HCV quasispecies (QS) characteristics have been a major focus of previous studies, yielding conflicting results. To obtain a comprehensive understanding of the role of HCV QS in antiviral therapy, we performed the largest-ever HCV QS analysis in 153 patients infected with HCV genotype 1 strains. A total of 4,314 viral clones spanning hypervarible region 1 were produced from these patients during the first 12 weeks of therapy, followed by detailed genetic analyses. Our data show an exponential distribution pattern of intrapatient QS diversity in this study population in which most patients (63%) had small QS diversity with genetic distance (d) less than 0.2. The group of patients with genetic distance located in the decay region (d>0.53) had a significantly higher early virologic response (EVR) rate (89.5%), which contributed substantially to the overall association between EVR and increased baseline QS diversity. In addition, EVR was linked to a clustered evolutionary pattern in terms of QS dynamic changes. Conclusion: EVR is associated with elevatedHCVQS diversity and complexity, especially in patients with significantly higher HCV genetic heterogeneity.

UR - http://www.scopus.com/inward/record.url?scp=73149108234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73149108234&partnerID=8YFLogxK

U2 - 10.1002/hep.23290

DO - 10.1002/hep.23290

M3 - Article

VL - 50

SP - 1765

EP - 1772

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 6

ER -